Active ingredientRelebactamCat. No. P-R028-001CAS 1174018-99-5Family · Pharmaceutical analytical standards
Relebactam
A beta-lactamase inhibitor used together with the antibiotic imipenem and with cilastatin: approved in 2019 in the United States, where it was withdrawn from the market in 2026, and in 2020 in Europe for serious Gram-negative infections with few treatment options. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?Unlike inhibitors such as clavulanic acid, it contains no beta-lactam ring: it belongs to the diazabicyclooctane family, the same as avibactam.
Go to the active ingredient →Active ingredientRelebactamCat. No. P-R028-001CAS 1174018-99-5
Isotopically labelledRelebactam-d4Cat. No. P-R028-002
NitrosamineN1-Nitroso RelebactamCat. No. P-R028-003
NitrosamineN2-Nitroso RelebactamCat. No. P-R028-004
Impurityent-RelebactamCat. No. P-R028-005No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.